Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Uridine API Manufacturers & Suppliers
1 verified results
Commercial-scale Suppliers
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Uridine | CAS No: 58-96-8 | GMP-certified suppliers
A medication that supports nucleic acid metabolism and is under investigation for potential benefits in cognitive function, neuroprotection, and metabolic disorder management.
Therapeutic categories
Product Snapshot
- Uridine is available in multiple formulation types including injection, powder for solution, and oral tablets suitable for intramuscular, intravenous, and oral administration routes
- Its primary therapeutic applications are under investigational status with ongoing research in various clinical indications
- Currently, Uridine holds an experimental designation and does not have FDA or EMA approval
Clinical Overview
While uridine itself does not have an established clinical indication as a standalone pharmaceutical agent, it is under investigation in experimental contexts related to cognitive function, neuroprotection, and certain metabolic disorders. Its investigational status reflects ongoing research rather than formal regulatory approval.
Pharmacologically, uridine participates in cellular processes including nucleic acid synthesis and membrane phospholipid metabolism. It can be phosphorylated intracellularly to uridine monophosphate (UMP) and subsequently to other pyrimidine nucleotides critical for RNA and DNA biosynthesis. This mechanism supports its role in nucleotide salvage pathways, contributing to nucleic acid repair and maintenance.
Absorption of uridine is generally efficient following oral administration, with rapid bioavailability. Distribution studies indicate cellular uptake across various tissues, including the central nervous system. Metabolism primarily involves phosphorylation to nucleotide derivatives and subsequent incorporation into RNA. Renal excretion of unmetabolized uridine is minimal due to its intracellular sequestration and utilization.
Safety and toxicity information for uridine as an isolated API is limited. Being an endogenous compound, it exhibits low toxicity profiles in physiological concentrations. Nonetheless, comprehensive toxicological assessments are warranted when developed for pharmaceutical use, particularly to evaluate effects related to nucleoside supplementation and systemic exposure.
Uridine is not currently marketed under specific brand names as an approved drug; its utilization is predominantly confined to experimental and investigational settings. When sourcing uridine API, critical quality attributes include high purity, consistent batch-to-batch reproducibility, and compliance with relevant pharmacopeial standards. Proper control of impurities, including related nucleosides and degradation products, is essential to ensure suitability for pharmaceutical development and regulatory submission.
Identification & chemistry
| Generic name | Uridine |
|---|---|
| Molecule type | Small molecule |
| CAS | 58-96-8 |
| UNII | WHI7HQ7H85 |
| DrugBank ID | DB02745 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| U6 snRNA-associated Sm-like protein LSm6 | Humans | |
| Nucleoside-specific channel-forming protein tsx | Escherichia coli (strain K12) |
Formulation & handling
- Uridine is a small molecule nucleoside available for both parenteral administration (intramuscular, intravenous) and oral delivery in solution and tablet forms.
- Its high water solubility and low logP (-2.4) support formulating aqueous injectable solutions and oral liquids with good bioavailability potential.
- Formulation handling should consider stability in aqueous media, especially for injectable powder reconstitution, and protection from degradation under storage conditions.
Regulatory status
Uridine is a type of Nucleoside and nucleotide analogs
Nucleoside and nucleotide analogs are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the development of antiviral and anticancer drugs. These compounds are structurally similar to natural nucleosides and nucleotides found in DNA and RNA, but they possess modified functional groups that enhance their therapeutic properties.
Nucleoside analogs are synthetic compounds composed of a nucleobase (adenine, cytosine, guanine, or thymine) and a sugar molecule, linked by a glycosidic bond. These analogs can act as competitive inhibitors of viral DNA or RNA synthesis by incorporating themselves into the growing nucleic acid chain, leading to premature termination of replication. This mechanism makes them effective against viral infections, including HIV, hepatitis B, and herpes.
On the other hand, nucleotide analogs are nucleoside analogs with an additional phosphate group attached to the sugar molecule. The presence of the phosphate group enhances their activity by providing an additional site for interaction with enzymes involved in nucleic acid synthesis. Nucleotide analogs are often used as prodrugs, requiring intracellular phosphorylation to become active. They have shown remarkable success in the treatment of certain types of cancer, particularly hematological malignancies.
The development and synthesis of nucleoside and nucleotide analogs require expertise in organic chemistry and medicinal chemistry. These compounds undergo rigorous testing to ensure their safety, efficacy, and compatibility with various drug formulations. The optimization of their pharmacokinetic and pharmacodynamic properties is a key focus during the drug development process.
In conclusion, nucleoside and nucleotide analogs are crucial components in the pharmaceutical industry's pursuit of effective antiviral and anticancer medications. Their unique structural modifications and mechanisms of action make them promising candidates for combating life-threatening diseases.
Uridine (Nucleoside and nucleotide analogs), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Uridine API manufacturers & distributors
Compare qualified Uridine API suppliers worldwide. We currently have 1 companies offering Uridine API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Zhejiang Xianfeng | Producer | China | China | CoA | 4 products |
When sending a request, specify which Uridine API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Uridine API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
